| 1 |
32070304 | The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. | 2020 Feb 18 |
3 |
| 2 |
30888624 | A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects. | 2019 May |
1 |
| 3 |
23930678 | Pharmacogenetics of olanzapine metabolism. | 2013 Aug |
2 |
| 4 |
22388157 | Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. | 2012 Apr |
1 |
| 5 |
22713701 | UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. | 2012 Aug |
5 |
| 6 |
21750471 | Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. | 2011 Sep |
1 |
| 7 |
20143052 | Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. | 2010 May |
4 |
| 8 |
17038872 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. | 2006 Oct |
2 |
| 9 |
12404680 | Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. | 2002 Jul |
2 |